Second line chemotherapy using gemcitabine and docetaxel for soft tissue sarcoma

Second line chemotherapy using gemcitabine and docetaxel for soft tissue sarcoma - Second line chemotherapy using gemcitabine and docetaxel for soft tissue sarcoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015917

Enrollment

Registered

2014-12-12

Start date

2015-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

soft tissue sarcoma except for small round cell tumor

Interventions

GEM (900 mg/m2 day 1, 8) + DOC (70 mg/m2 day 8) 5 courses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with soft tissue sarcoma except for small round cell tumor after failure of adriamycin based chemotherapy who expresses his/her assent

Exclusion criteria

Exclusion criteria: patient who doesn't show his/her assent patient considered to be not suitable for participating this trial

Design outcomes

Primary

Measure	Time frame
reduction of tumor volume	—

Secondary

Measure	Time frame
adverse effect	—

Countries

Japan

Contacts

Public ContactAkihito Nagano

Gifu University school of medicine The department of Orthopaedic surgery

a-nagano@lucky.odn.ne.jp0582306333

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026